Abstract-Although both hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) are potent angiogenic growth factors in animal models of ischemia, their characteristics are not the same in animal experiments and clinical trials. To elucidate the discrepancy between HGF and VEGF, we compared the effects of HGF and VEGF on endothelial progenitor cells under angiotensin II stimulation, which is a well-known risk factor for atherosclerosis. Here, we demonstrated that HGF, but not VEGF, attenuated angiotensin II-induced senescence of endothelial progenitor cells through a reduction of oxidative stress by inhibition of the phosphatidylinositol-3,4,5-triphosphate/rac1 pathway. 
C ritical limb ischemia is estimated to develop in 500 to 1000 individuals per million per year. 1 In a large proportion of these patients, the anatomic extent and distribution of arterial occlusive disease make the patients unsuitable for operative or percutaneous revascularization, and there is no optimal medical therapy for such critical limb ischemia. 1 Therefore, therapeutic angiogenesis using angiogenic growth factors, such as vascular endothelial growth factor (VEGF), 2 has been investigated. Although initial openlabel clinical trials using VEGF were successful, doubleblind, placebo-controlled clinical trials failed to show efficacy in peripheral arterial disease (PAD) patients. 3 On the other hand, recent clinical trials using hepatocyte growth factor (HGF) plasmid DNA demonstrated a marked difference between HGF and VEGF, because there was no evidence of edema in patients transfected with the human HGF gene, in marked contrast to a VEGF trial in which 60% of patients developed moderate or severe edema. More recently, a multicenter, double-blind, placebo-controlled phase III clinical trial using HGF plasmid DNA in Japan demonstrated a significant improvement in primary end points as compared with placebo (70.4% versus 30.8%; Pϭ0.014). In addition, a multicenter, double-blind, placebo-controlled phase II US clinical trial using HGF plasmid DNA demonstrated a significant increase in transcutaneous partial pressure of oxygen as compared with placebo. 4 To elucidate the molecular difference between HGF and VEGF, we focused on the effects of HGF and VEGF on endothelial progenitor cells (EPCs) under angiotensin (Ang) II stimulation, because EPCs play a significant role in the neovascularization of ischemic tissue. However, their functional activity was markedly impaired in patients with PAD and coronary artery disease 5, 6 in whom the local renin-angiotensin system was activated. Because the number of circulating EPCs was negatively correlated with risk factors for PAD, such as hypertension 7 and diabetes mellitus, 8 these risk factors would shorten the average life span of EPCs, leading to impairment of neovascularization. Here, we demonstrated that HGF, but not VEGF, attenuated Ang II-induced senescence of EPCs through a reduction of oxidative stress by inhibition of the PIP3/rac1 pathway.
Materials and Methods
Please see the online supplemental data (http://hyper.ahajournals.org) for information on the primary antibodies and reagents used in the study. ng/mL), or superoxide dismutase (SOD; 50 U/mL), were added every 48 hours starting on day 8. The protocol of the in vitro study is shown in Figure S1A . Please see the online supplemental data for a complete description of cell isolation and culture.
HGF Transgenic Mice
We generated mice (C57BL6 background) with cardiac-specific (␣-major histocompatibility complex driven) overexpression of HGF in which serum HGF derived from the heart was significantly increased (Please see the online supplemental data about the characteristics of HGF transgenic [Tg] mice).
Ischemic Hindlimb Animal Model and Bone Marrow Transplantation Model
Please see the online supplemental data for a complete description of the ischemic hindlimb model, bone marrow transplantation, and tissue samples used for these studies.
Western Blotting
Protein analysis using Western blotting was performed as described previously. 9 
Statistical Analysis
Values are expressed as meansϮSEs. ANOVA and t test, followed by Bonferroni adjustment for multiple comparisons, were used for comparisons of Ͼ2 groups. A P value of Ͻ0.05 was considered to indicate significance of mean differences.
Results

Antisenescent Action of HGF
Initially, we examined the effects of HGF and VEGF on the growth of EPCs under continuous Ang II stimulation. Consistent with previous reports, 10 continuous stimulation with Ang II significantly reduced the number of EPCs as compared with control, whereas HGF and VEGF significantly stimulated the proliferation of EPCs ( Figure 1A ). Addition of either HGF or VEGF attenuated the decrease in EPC number induced by Ang II. Then, we focused on the effects of HGF and VEGF on Ang II-induced senescence, because Ang II is known to promote senescence of EPCs mainly through oxidative stress. 11 Interestingly, HGF and SOD, but not VEGF, significantly attenuated Ang II-induced senescence of EPCs as determined by senescence associated ␤-galactosidase staining ( Figure 1B) , although HGF and VEGF alone promoted EPC senescence. Moreover, HGF and SOD significantly inhibited the induction of p53, p21
Cip1 , and p16 INK4a by Ang II ( Figure  S1B ), which induces cell premature senescence through oxidative stress. 12 Next, we examined the function of EPCs. As show in Figure S2A , S2B, and S2C, the incorporation ability into tube-like structures of human umbilical cord endothelial cells and proliferative activity were significantly decreased in the Ang II single-treated group. However, pretreatment with HGF and SOD, but not VEGF, significantly attenuated the decrease in their incorporation and proliferation.
To elucidate the role of oxidative stress, the production of superoxide was measured by dihydroethidium staining. Interestingly, the production of superoxide induced by Ang II was significantly reduced by pretreatment with HGF and SOD, but not VEGF, whereas HGF and VEGF alone significantly increased superoxide production (Figure 2A and 2B) . The antioxidative effect of HGF was also confirmed in bovine aortic endothelial cells ( Figure S3A ). In addition, pretreatment with HGF and SOD significantly reduced the Ang II-induced gp91phox expression ( Figure S3B ), which is one of the components of NADPH oxidase and known to be upregulated by Ang II in EPCs. 11 Although a previous report shows that VEGF accelerates EPC incorporation into the tube-like structure of endothelial cells in the acute phase, 13 our data clearly showed that, because under basal conditions HGF and VEGF act as pro-oxidants, chronic stimulation with HGF and VEGF caused the decrease in EPC function. However, in the presence of Ang II, HGF, but not VEGF, can act as an antioxidant.
Upstream Molecular Mechanisms of Inhibition of Oxidative Stress by HGF
The production of reactive oxygen species (ROS) by Ang II is rac1 dependent in EPCs, because dominant-negative rac1 transfection reduced Ang II-induced ROS production ( Figure  2A ). Ang II increased GTP-rac1 with 2 peaks (at 10 and 60 minutes; data not shown), whereas pretreatment with HGF, but not VEGF, prevented Ang II-induced rac1 binding to GTP at 60 minutes ( Figure 3A) . HGF also prevented Ang II-induced rac1 translocation from the cytosol to the plasma membrane ( Figure S4A ). The product of phosphatidylinositol 3-kinase activity, PI (3, 4, and 5) P3 (PIP3), is required to activate a number of rac-specific guanine nucleotide exchangers in endothelial cells. 14 Indeed, phosphatidylinositol 3-kinase-specific inhibitors LY294002 and wortmannin, but not the P38 mitogen-activated protein kinase inhibitor SB203580 or the mitogen-activated protein kinase kinase inhibitor PD98059, significantly reduced rac1 binding to GTP induced by Ang II (PϽ0.01 versus Ang II; Figure 3B ). Then we examined the PIP3 production, and, finally, we found that pretreatment with HGF significantly inhibited Ang II-induced PIP3 production, whereas VEGF did not inhibit it ( Figure 3C ). Previous reports show that Ang II- 15 and VEGF- 16 induced phosphorylation of Akt depends on ROS; on the other hand, HGF-induced phosphorylation of Akt is independent of ROS. 16 Consistently, pretreatment with HGF, but not VEGF, significantly inhibited Ang II-induced phosphorylation of Akt in EPCs ( Figure S4B ).
As the end point of the in vitro experiment, we focused on endothelial cell tube formation under continuous Ang II stimulation. Ang II alone had a modest effect on tube formation of HUVECs after 12 hours, but the formed tubes were collapsed compared with control after 72 hours. However, interestingly, pretreatment with HGF, but not VEGF, decreased their collapse, and maintained tube formation even after 72 hours ( Figure 4A and 4B).
Comparison of Neovascularization in Hindlimb Ischemia Nude Mouse Model
To confirm the function of ex vivo expanded human EPCs in vivo stimulated with in vitro study protocol, incorporation of fluorescent carbocyanine1,1Ј-dioctadecyl-1 to 3,3,3Ј3Ј-tetramethylidocarboyanine perchlorate (DiI) labeled human EPCs and their contribution to host neovascularization were investigated in a nude mouse hindlimb ischemia model. At 7 days after induction of ischemia, the Ang II-treated EPC group showed significantly decreased incorporation compared with the control group, whereas the Ang IIϩHGF group, but not the Ang IIϩVEGF group, showed significant attenuation of the decrease ( Figure 5A and 5B). Moreover, the Ang II-treated EPC group showed significant attenuation of the increase in host mouse capillary density compared with the control group, whereas the Ang IIϩHGF group, but not the Ang IIϩVEGF group, showed a significant increase. These in vitro and in vivo data showed that HGF reduced Ang 
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II-induced senescence of EPCs through an antioxidative effect, which maintained the function of neovascularization.
Ang II Infusion Into HGF Transgenic Mice
To further investigate the effect of HGF on Ang II-induced senescence in EPCs, we made Tg mice with cardiac-specific overexpression of human HGF in which the blood level of the human HGF protein was significantly increased ( Figure  S5A ). We administered Ang II (0.7 mg/kg per day) to HGF Tg mice and wild-type (WT) mice. There was no significant difference in blood pressure between WT and HGF Tg mice after Ang II infusion ( Figure S5B ). After infusion of Ang II, peripheral blood-derived ( Figure S6A ) and bone marrowderived ( Figure S6B ) monocytic EPCs were significantly decreased in WT mice as compared with HGF Tg mice. The rate of senescence was significantly reduced in HGF Tg mice as compared with WT mice at 4 weeks ( Figure S6C ). Moreover, as show in Figure S6D , HGF Tg mice showed a significant reduction of Ang II infusion-induced gp91 phox protein expression in total bone marrow mononuclear cells as compared with WT mice (PϽ0.01).
Based on these results, we finally used a hindlimb ischemia model after Ang II infusion for 1 week. Blood flow ratio and the relative increase in capillary density in Ang II-treated HGF Tg mice were significantly increased as compared with those in Ang II-treated WT mice ( Figure S7A , S7B, S7C, and S7D). Attenuation of the impairment of neovascularization by Ang II in HGF Tg mice was accompanied by a significant increase in the number of bone marrow-derived EPCs, whereas Ang II infusion significantly decreased the number in WT mice ( Figure S7E and S7F).
Discussion
Both HGF and VEGF are potent angiogenic growth factors in animal models of ischemia, but their characteristics are not In this study, we clearly demonstrated that Ang II accelerated EPC senescence through oxidative stress, as reported previously, 11 which aggravated the impairment of EPC function in vivo and in vitro. Ang II alone had a modest effect on tube formation of HUVECs in the short term (12 hours); moreover, Ang IIϩVEGF showed the tendency to form tubular formation compared with VEGF alone after 12 hours, as described previously, 13 but the formed tubes collapsed compared with control in the long term (72 hour). We also demonstrated that, under basal conditions, HGF and VEGF significantly stimulated proliferation of EPCs and tube formation of HUVECs (12 hours), but they also increased ROS production, leading to replicative senescence and ROSinduced premature senescence of EPC. Interestingly, finally, we also found that pretreatment with HGF, but not VEGF, significantly reduced Ang II-induced ROS and senescence in EPCs through a reduction of Ang II-induced PIP3/rac1 activity, leading to maintained function of EPCs and tube formation of HUVECs, even after 72 hours.
Consistent with these findings, pretreatment with HGF, but not VEGF, decreased Ang II-induced Akt phosphorylation ( Figure S4B ). As for cell senescence and Akt activation, Miyauchi et al 21 showed that Akt activity increased with cellular senescence, and inhibition of Akt extended the life span of endothelial cells; thus, constitutive activation of Akt might promote senescence.
Recently, it has become more clear that VEGF is not only an angiogenic growth factor but also a proinflammatory cytokine. 22, 23 VEGF leads to increased monocyte adhesion to endothelial cells, which is mediated by ROS (rac1)-nuclear factor B activation 24, 25 and promotes atherosclerotic plaque formation without increased microvessel development. 26 From this viewpoint, HGF is unique, because HGF is known to act as an anti-inflammatory cytokine 22, 27 and as an antioxidative stress cytokine. 28 Min et al 22 showed that HGF prevented the increase in expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 induced by VEGF, through inhibition of nuclear factor B activation. The present study also indicates the possibility that HGF might inhibit VEGF-induced inflammation through a reduction of oxidative stress.
We showed different effects of HGF and VEGF on PIP3/rac1 activity under Ang II stimulation but could not show its upstream mechanism. Recent articles revealed that SH2 domain-containing inositol 5-phosphatase binds to the epidermal growth factor receptor, which contributes to PIP3/ Akt activation, and SH2 domain-containing inositol 5-phosphatase also binds to c-Met directly and is involved in HGF-induced cell scattering. In addition, Ang II-induced rac1 activation and ROS production are mediated by epidermal growth factor receptor. 29 These reports and our experiment suggest the possibility that translocation of SH2 domain-containing inositol 5-phosphatase between c-Met and epidermal growth factor receptor controls their signaling and ROS production. Careful research is necessary to clarify this mechanism in the future.
Certainly, our experiment demonstrated that HGF, but not VEGF, significantly attenuated the Ang II-induced impairment of neovascularization by reducing oxidative stress in EPCs. On the other hand, Ushio-Fukai and colleagues 30, 31 reported that neovascularization in the ischemic hindlimb is significantly impaired in gp91phox Ϫ/Ϫ mice, and the ROS-generating agent LY83583 improved their neovascularization. This and our experiment suggest that conditions of excess or insufficient ROS may also impair neovascularization.
In this experiment, to reproduce the conditions of a clinical trial, we compared the effect of high-dose HGF (100 ng/mL) and VEGF (100 ng/mL) on neovascularization. However, Ehrbar et al 32 showed that controlling the level of VEGF with special delivery systems (␣2PI 1-8 -VEGF 121 ) results in nonleaky vessels and increased vessel formation more potently than did native VEGF 121 . We should consider the possibility that slow-release, low-dose VEGF might be effective in clinical trials.
Perspectives
Overall, the present study demonstrated that HGF, but not VEGF, attenuated senescence induced by Ang II in EPCs. These protective effects of HGF on senescence and oxidative stress in EPCs and endothelial cells might contribute to the clinical use of therapeutic angiogenesis using the HGF gene observed in clinical trials. The present study suggests ideal features of future angiogenesis therapy using angiogenic growth factors. In the future, HGF gene therapy could be applied for ischemic heart disease. were co-plated and incubated at 37 °C for the indicated times on a growth factor-reduced Matrigel-coated 24-well dish. Incorporation of EPC in tubules was determined in 10 random fields.
Superoxide was detected in vitro by dihydroethidium (DHE) (10 µmol/L) staining, as described previously 4 . C-myc-tagged dominant negative rac1 (N17Rac1) was transfected using LipofectAMIN 2000 (Invitrogen), as previously described 5 .
Phosphatidylinositol 3, 4, 5 phosphate (PI (3,4,5) P3) activity was quantified using a PIP3 mass strip assay kit from Echelon Biosciences Inc.
HGF Tg mice
Previous report revealed that mice over-expressing HGF/SF in the kidney demonstrated prominent tubular cyst with progressive glomerulosclerosis, and were susceptible to premature death from renal failure 6 . Because HGF regulates morphogenesis of various types of cells, HGF may produce cysts in some organs. To avoid this effect, we didn't select kidney or liver but heart, which rarely has cyst. We generated mice with cardiac-specific (α-MHC driven) over-expression of human HGF, and its serum human HGF was significantly increased (Fig. S5a) . There is no significant difference in cardiac function or blood pressure between WT (littermate) and HGF Tg mice (Fig. S5b) , and also no tubular cyst in the kidney or liver. In addition, liver and kidney function of HGF Tg are not impaired compared to their littermates (Fig. S5a) .
Ischemic hindlimb animal model
All procedures were performed in accordance with the Institutional Animal
Committee of Osaka University School of Medicine. Male athymic nude mice, HGF Tg mice and C57BL6 mice (littermates) aged 8-10 weeks were anesthetized with pentobarbitone for operative resection of one femoral artery, as described previously 2 7 .
One day after operation, athymic nude mice were given an intravenous injection of 
Bone marrow transplantation
Under sterile conditions, bone marrow cells were isolated from 8-week-old male C57BL6 transgenic mice that ubiquitously expressed enhanced green fluorescent protein (GFP). Then, 6-8-week-old HGF Tg mice or C57BL6 mice (littermates) were lethally irradiated with 10 Gy. For total bone marrow transplantation, each irradiated recipient received 5 10 6 bone marrow cells from GFP transgenic mice. A total of 85% to 95% of peripheral MNC had been reconstituted as determined by flow cytometry.
Blood tests and blood pressure measurement
Blood tests were performed after 12 hr starvation and blood pressure was measured by the tail cuff method. HGF, but not VEGF, attenuated Ang II-induced EPC senescence.
(a) Protocol of in vitro study. (b) Expression of CDKIs on day 14 in EPC. Ang II = Ang II (10 -9 -10 -7 M), HGF = HGF 100 ng/ml, VEGF = VEGF 100 ng/ml, SOD = SOD 50 U/ml. n=4-5.
